Aclarion Inc (ACON) 시세

They must be planning a major share price boost or reverse split, this should be trading on the OTC now if I am not mistaken?

Personal Injury News was Huge and went unnoticed

Ready - anytime

Let’s see later
Some PR AH and boom 💥

someone is loading big time at 0.2250s

company did get european patent approval yesterday but no pr out

bought some should see European patent news

No volume low - wait for it

ACON new 52 week low

Looks ready

When mooning?

50ma/20ma cross

Big volume guided the way a few weeks ago

How high of a moon? ....Thanks!!!

Moon soon

Knock knock… who’s there?

Picked up a popcorn bag full earlier at $.328 just for the heck of it.

grabbed some post market. runs like hell in the past. we shall see.

Hang on Invest, I am sure you're Bull is coming Lol

ACON: "But don't tell my heart, my ACON breaky heart
I just don't think he'd understand;
And if you tell my heart, my ACON breaky heart
He might blow up and kill this man!!"


(Mr. Billy, & his CHARMING Daughter!!!)

Company used some of it's pocket change to run the price up over $.09 earlier so they could dump a gazillion under $.08. Hummmmm ....

Seems like a PR (no matter how hokey it might be) would have been a better strategy.

Something to the effect: "We have discovered what we believe to be a revolutionary way to keep our patients from pooping while being given certain treatments. We'll be looking to file a patent on this amazing discovery just as soon as we can raise enough cash to pay for the initial patent fee."

NOW we're starting to talk! YEAH BABY!

Love these dumping prices. MORE!!!

Got some at $.4099 a bit ago. Good price IMO.

It’s super thin slap that ask

Yes I saw that

Just announced, CLOSED

Aclarion Announces Closing of $3.0 Million Public Offering

Source: GlobeNewswire Inc.

via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.58. The common warrants are immediately exercisable at a price of $0.58 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.
Gross proceeds, before deducting placement agent fees and other offering expenses, are approximately $3.0 million.

Maxim Group LLC acted as sole placement agent in connection with this offering.

The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-275989) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the "SEC") on February 26, 2024. The offering was made only by means of a prospectus which is a part of the Registration Statement. A copy of the final prospectus relating to the offering has been filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements.

All of our forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Registration Statement, as well as other disclosures contained in such Registration Statement and the Company’s other filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com

Closing tomorrow it should go back up

Sold at 71 cents premarket today after buying at 60 cents and loaded back up under 32 cents on bigger dip. Hope to sell at 50 cents or above

Sold at 71 cents premarket today after buying at 60 cents and loaded back up under 32 cents on bigger dip. Hope to sell at 50 cents or above

ACON new 52 week low

Rentry today on dip premarket.. 0.6093 average

ACON has no technical synchronicity except on the short end. $1 is often a pit stop but that point is showing no favor either. It's on my watchlist but nothing more. https://schrts.co/CYDkRKKW

ACON new 52 week low

ACON new 52 week low

ACON new 52 week low

ACON new 52 week low

ACON new 52/week low

ACON new 52 week low

ACON new 52 week low

And here it goes again up 100%

ACON new 52 week low

HERES WHY
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173581186

well that didn't last.

6.81 Damn
Message in reply to:

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

ACON FLYING ON NEWS: https://www.globenewswire.com/news-release/2024/01/08/2805404/0/en/Aclarion-and-ATEC-Execute-Strategic-Partnership-Agreement-to-Advance-Commercialization-of-Nociscan.html



BUT ANOTHER HIGH RISK LOW CASH RUNNER CYCC SPEC
Overall Risk
High
Offering Ability
High
Overhead Supply
High
Historical
High
Cash Need
High
https://dilutiontracker.com/app/search/ACON?a=dbb88c

Again

Damn